NEW YORK (GenomeWeb) – CombiMatrix reported after the close of the market Wednesday that its fourth quarter revenues rose 21 percent, driven by increases in the company's reproductive testing, particularly in miscarriage analysis and preimplantation genetic screening.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.